91895-30-6

Basic information

• Product Name: 2,3-DICHLORO-6,7-DIFLUOROQUINOXALINE
• Synonyms: 2,3-DICHLORO-6,7-DIFLUOROQUINOXALINE
• CAS NO: 91895-30-6
• Molecular Formula: C₈H₂Cl₂F₂N₂
• Molecular Weight: 235.0176864
• Mol File: 91895-30-6.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2,3-DICHLORO-6,7-DIFLUOROQUINOXALINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-DICHLORO-6,7-DIFLUOROQUINOXALINE(91895-30-6)
• EPA Substance Registry System: 2,3-DICHLORO-6,7-DIFLUOROQUINOXALINE(91895-30-6)

Safety Data

• Hazardous Substances Data: 91895-30-6(Hazardous Substances Data)

Usage

General Description

2,3-dichloro-6,7-difluoroquinoxaline is a chemical compound with the molecular formula C8H2Cl2F2N2. It is a heterocyclic aromatic compound with a fused six-membered ring and a five-membered ring containing two nitrogen atoms. 2,3-dichloro-6,7-difluoroquinoxaline is widely used as a building block in the synthesis of pharmaceuticals and agrochemicals, and it possesses potential antimicrobial, antifungal, and anticancer properties. It is also used as a reagent in organic synthesis and medicinal chemistry due to its ability to form various derivatives for further research and applications. The compound is typically handled and stored in a controlled environment due to its potential hazards, including irritant and toxic effects on human health and the environment.

Upstream product

• 91895-29-3 6,7-difluoro-1,4-dihydro-2,3-quinoxalinedione 
• 91895-29-3 2,3-dihydroxy-6,7-difluoroquinoxaline 
• 76179-40-3 2-amino-4,5-difluoroaniline 

Relevant articles and documents

FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY

The present invention relates to certain certain fused tricyclic heteroaryl rings compounds of the Formula (I) (also referred to herein as the "Fused Tricyclic Compounds"), wherein M, Q, U, W, X, Y, Z, R1, R2, and R3, and rings C and D are as herein described. The present invention also provides compositions comprising at least one Fused Tricyclic Compound, and use of such compounds in the treatment of central nervous system diseases or disorders such as Parkinson's disease.

Imidazo[1,2-a]quinoxalin-4-amines: A novel class of nonxanthine A1- adenosine receptor antagonists

The syntheses and A1 adenosine receptor affinities of a number of imidazo[1,2-a]quinoxalin-4-amines are reported. Structure-activity relationships within the series and in comparison with other similar tricyclic nonxanthine adenosine antagonists are discussed, leading to a putative common binding mode of these nitrogen-containing heterocycles to A1 adenosine receptors. Secondary amino compounds displayed the best affinities toward A1 receptors, while the tertiary amines were almost devoid of activity, thus suggesting a crucial role for the hydrogen bond-forming 4-NH group. Remarkably higher potencies for 1-methyl and N-cyclopentyl derivatives were also found. 4-Cyclopentylamino-1-methylimidazo[1,2-a]quinoxaline (IRFI 165) is the most potent compound in this series, having K(i)(A1) = 7.9 nM. It is also provided with a good A1 selectivity both versus A(2a) and A3 subtypes and was selected for further pharmacological studies.

Method of using [1,2,4]triazolo[4,3-a]quinoxaline-4-amine derivatives as antidepressant and antifatigue agents

A series of novel [1,2,4]triazolo[4,3-a]quinoxaline-4-amine derivatives wherein the amine group is optionally substituted with lower alkyl, phenylalkyl having up to three carbon atoms in the alkyl moiety or alkanoyl having from two to five carbon atoms, or the amine group alternatively completes a piperazino ring, the quinoxaline ring is optionally substituted with fluorine, chlorine, bromine or methoxy, and the triazolo ring is optionally substituted with lower alkyl, lower perfluoroalkyl or phenyl are disclosed. These novel compounds are useful for treatment of symptoms associated with depression. Also disclosed are pharmaceutical compositions containing the novel compounds of this invention and a method of using the compounds in the treatment of depression and fatigue.